sponsored
PatientsVille.com Logo

PatientsVille

Hydroxychloroquine Medical Research Studies

Up-to-date List of Hydroxychloroquine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hydroxychloroquine Medical Research Studies

Rank Status Study
1 Recruiting Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Intervention: Drug: sirolimus and Hydroxychloroquine
Outcome Measure: safety of everolimus and Hydroxychloroquine
2 Recruiting Metabolic Effects of Hydroxychloroquine
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Hydroxychloroquine;   Other: Hydroxychloroquine Placebo
Outcome Measures: Insulin sensitivity determined by hyperinsulinemic euglycemic clamp;   Effect of HCQ on fasting blood glucose;   Effect of HCQ on fasting low density lipoprotein;   Effect of HcQ on serum biomarkers of inflammation
3 Recruiting Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine;   Drug: Sirolimus;   Drug: Vorinostat
Outcome Measure: Maximum Tolerated Dose (MTD)
4 Recruiting Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: Hydroxychloroquine (HC)
Outcome Measures: Measure biologic markers of autophagy in tumor and normal tissues (peripheral blood mononuclear cells, renal parenchyma) following a short course of pre-operative oral Hydroxychloroquine [HC] in patients with renal cell carcinoma.;   Measure the serum biomarker response (HMGB1, sRAGE, VEGF, fibronectin, CRP, IL-6, nicotinamide N-methyltransferase, thrombospondin-1, CD 14, and ferritin) following pre-operative oral HC.;   Assess the effect of pre-operative HC on phenotype and function of DC and NK cells;   Assess the effect of pre-operative HC on abundance of neutrophils, NK cells, T-cells and T-cell subsets, PDCs and MDCs in the resected tumor, expression of CAIX and NOX4 compared with matched age/sex/histology matched controls.;   Assess miRNAs pre and post HC and postoperatively in blood and in resected tumor and normal kidney compared to stage- and grade-matched controls.
5 Recruiting Preventive Approach to Congenital Heart Block With Hydroxychloroquine
Conditions: Congenital Heart Block;   Neonatal Lupus;   Autoantibody-Associated Heart Block
Intervention: Drug: Hydroxychloroquine
Outcome Measures: Recurrence of advanced heart block;   Prolonged PR interval (>150msec);   Any sign of myocardial injury, without change in cardiac rate or rhythm;   Echocardiographic densities consistent with EFE confirmed postnatally;   Fetal death not related to cardiac dysfunction;   NL rash;   Prematurity;   Birth weight <10% in the context of gestational age;   Abnormal fluid collection
6 Recruiting Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Conditions: Non-small Cell Lung Cancer;   Advanced Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Hydroxychloroquine;   Drug: Bevacizumab
Outcome Measures: Antitumor activity, as measured by tumor response rate of Hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer;   Time to progression;   Survival;   Overall survival;   Toxicity of Hydroxychloroquine, paclitaxel, carboplatin, and bevacizumab (for eligible patients) in patients with advanced or recurrent NSCLC cancer
7 Recruiting Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
Condition: Malignant Solid Tumour
Interventions: Drug: Hydroxychloroquine ( HCQ);   Drug: Vorinostat (Suberoylanilide Hydroxamic Acid)
Outcome Measures: Maximum tolerated dose (MTD) of Hydroxychloroquine (HCQ) in combination with Vorinostat in patients with advanced solid tumors;   To evaluate the safety and tolerability of HCQ in combination with Vorinostat in this patient population as determined by toxicity profile, incidence and rating according to NCI/CTC v3.0 criteria.;   To evaluate the antitumor activity of HCQ in combination with Vorinostat as determined by response rate and progression free survival (exploratory)
8 Recruiting Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Capecitabine;   Drug: Hydroxychloroquine;   Radiation: Proton or Photon Radiation Therapy
Outcome Measures: Progression-free survival;   Pathologic response rate;   Overall survival;   Toxicity/Adverse events;   Surgical morbidity;   Post-operative Mortality;   Biomarkers;   Pathologic down-staging;   Local control
9 Unknown  Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib;   Drug: Hydroxychloroquine;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
Outcome Measures: Dose-limiting toxicity;   Maximum tolerated dose of Hydroxychloroquine;   Myeloma response (stringent complete response [sCR], CR, very good partial response [VGPR], PR, stable disease, and progressive disease);   Overall survival;   Time to treatment failure;   Progression-free survival;   Time to response;   Duration of overall response;   Correlation of Hydroxychloroquine and its metabolites blood levels with efficacy by mass spectrometry;   Pre- and post-bortezomib proteasome inhibition assays;   Bone marrow aspirate and peripheral blood mononuclear cell analysis for aggresome formation, autophagy inhibition, and apoptosis;   Rate of overall adverse events and serious adverse events
10 Recruiting Cyclophosphamide(Cy)/ Dexamethasone(Dex)/Rapamycin (Rapa)/Hydroxychloroquine (HCQ) for Relapsed or Refractory Myeloma(Rel/Ref MM)
Condition: Multiple Myeloma
Interventions: Drug: Hydroxychloroquine;   Drug: Rapamycin
Outcome Measures: Maximum tolerated dose (MTD)of Hydroxychloroquine (HCQ),Rapamycin, Dexamethasone, and Cyclophosphamide.;   Evaluation of biological activity;   Evaluation of efficacy
11 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: Hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD of Akt inhibitor MK-2206 as assessed by CTCAE version 4.0;   Dose-limiting toxicity rate as assessed by CTCAE version 4.0;   Changes in expression pattern of markers Beclin1, LC3, and p62 by immunohistochemistry (IHC), Western blotting, and number of autophagosomes by electron microscope (EM);   Change in autophagy activity induced by Hydroxychloroquine as measured by the amount of autophagosomes by EM;   Validation of Beclin1, LC3, and p62 as markers for autophagy measured by EM
12 Recruiting Antibiotics and Hydroxychloroquine in Crohn's
Condition: Crohn's Disease
Interventions: Drug: Ciprofloxacin;   Drug: Doxycycline;   Drug: Hydroxychloroquine;   Drug: Budesonide
Outcome Measures: • Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without addition of any other medication or treatment for the Crohn's Disease.;   • Remission, defined as CDAI ≤150 maintained through to 24 weeks;   • Remission, defined as CDAI ≤150 maintained through to 52 weeks;   • Remission defined as CDAI <150 at 4 weeks;   • Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks;   • Markers of cost (days admitted to hospital, days unable to carry out normal daily activities, need for surgery);   • Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal;   • Patient global assessment of symptom severity by 10 cm visual analogue score at 4 weeks, at 10 weeks, or Early Withdrawal;   • Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at each visit;   • Fall in Faecal Calprotectin
13 Recruiting Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine;   Drug: abraxane;   Drug: Hydroxychloroquine
Outcome Measures: Histologic response to pre-operative gemcitabine/ nab-paclitaxel;   Carbohydrate antigen 19-9 (CA19-9) response to pre-operative gemcitabine/ nab-paclitaxel;   Rate of R0 resection and positive lymph node ratio
14 Recruiting A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Drug: Sirolimus and Hydroxychloroquine
Outcome Measures: The SUVmax change on PET/CT scan;   Tumor response;   The toxicity
15 Recruiting Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Condition: Porphyria Cutanea Tarda
Interventions: Drug: Hydroxychloroquine;   Procedure: Phlebotomy
Outcome Measure: Normal plasma porphyrin concentration
16 Recruiting Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Drug: XELOX regimen;   Drug: Hydroxychloroquine
Outcome Measures: Progression-free survival;   Overall response rate;   Duration of response;   Disease-control rate
17 Recruiting Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Hydroxychloroquine;   Drug: IL-2
Outcome Measures: Proportion of patients with metastatic RCC treated with IL-2 + HCQ at 1200mg/d who experience a clinical complete response.;   Complete response (CR), overall survival (OS) and time to progression (TTP) of patients with metastatic RCC treated with IL-2 + HCQ to the historical data of patients treated with high dose IL-2 alone in the CWG data base.;   Safety/toxicity of IL-2 + HCQ compared to CWG database of metastatic RCC patients treated with IL-2 alone: # doses IL-2 during 1st course; toxicity after scheduled 9th dose IL-2; frequency grade III and IV or unexpected or rare toxicities;   Baseline laboratory parameters outlined under "description" (to be correlated with toxicity, response, and survival).;   Known prognostic criteria for RCC patients (Motzer criteria, performance status, prior nephrectomy, presence of liver and/or bone metastases categories) on clinical outcome.
18 Recruiting Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases
Conditions: Bone Metastases;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Hydroxychloroquine;   Radiation: radiation therapy
Outcome Measure: MTD of Hydroxychloroquine that can be safely administered to cancer patients in association with radiotherapy
19 Recruiting Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
Condition: HIV Infection
Intervention: Drug: Hydroxychloroquine
Outcome Measure: Change in CD4 from baseline
20 Unknown  Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Hydroxychloroquine;   Drug: temsirolimus;   Other: electron microscopy;   Other: high performance liquid chromatography;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: autophagy inhibition therapy
Outcome Measures: Maximum tolerated dose of Hydroxychloroquine;   Response rate;   Toxicity rate as assessed by NCI CTCAE v. 3.0;   Pharmacokinetic and pharmacodynamic correlative endpoints

These studies may lead to new treatments and are adding insight into Hydroxychloroquine etiology and treatment.

A major focus of Hydroxychloroquine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hydroxychloroquine